Cloniprazepam, a benzodiazepine derivative, serves as a prodrug for clonazepam, generating 7-aminoclonazepam and various other metabolites. Among these minor metabolites are 3-hydroxyclonazepam, 6-hydroxyclonazepam, 3-hydroxycloniprazepam, and ketocloniprazepam, which features a ketone group formed in place of the 3-hydroxy group. Cloniprazepam is categorized as a designer drug and falls under the umbrella of “new psychoactive substances” (NPS). Towards the conclusion of 2017, it remained unregulated in most countries.
Clonazepam is a benzodiazepine derivative and a prodrug of clonazepam, which means it metabolizes into clonazepam and other related compounds within the body.
What are the minor metabolites of Clonazepam?
Minor metabolites of Cloniprazepam include 3-hydroxyclonazepam, 6-hydroxyclonazepam, 3-hydroxycloniprazepam, and ketocloniprazepam, the latter featuring a ketone group formed in place of the 3-hydroxy group.
Is Clonazepam a designer drug?
Yes, Cloniprazepam is considered a designer drug and falls under the category of “new psychoactive substances” (NPS).
Is Cloniprazepam regulated in most countries?
As of the end of 2017, Cloniprazepam remained an uncontrolled substance in many countries.
References
Moosmann B, Bisel P, Franz F, Huppertz LM, Auwärter V (November 2016). “Metabolic Characterization of Designer Benzodiazepines”This study provides an update on the in vitro phase I microsomal metabolism of designer benzodiazepines. The research covers various compounds, including adinazolam, cloniprazepam, fonazepam, 3-hydroxyphenazepam, metizolam, and nitrazolam.
Mortelé O, Vervliet P, Gys C, et al. (May 2018). “Metabolism Study of Cloniprazepam Using Liquid Chromatography and Mass Spectrometry”This research delves into the in vitro phase I and phase II metabolism of cloniprazepam, a new designer benzodiazepine. The study employs liquid chromatography coupled to quadrupole time-of-flight mass spectrometry to analyze the compound’s metabolic pathways.
